| |MARCH 20269INDOCO REMEDIES GETS US FDA APPROVAL FOR BRIVARACETAM ORAL SOLUTIONERIS LIFESCIENCES AND NATCO TIES UP FOR SEMAGLUTIDE ROLLOUTThe US FDA has approved the final approval of brivaraceta m oral solution, 10 mg/mL, which is a generic version of the Briviact 10 mg /mL of UCB, Inc. The license allows Indoco to sell brivaracetam oral solution in America.Brivaracetam oral solution is a type of anticonvulsant utilized in treating partial-onset seizures amongst patients as young as 1 month of age. It was established that it is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), which is Briviact 10 mg/mL. The product will be produced in the state-of-the-art plant of Indico Remedies in Verna, Goa, India.Aditi Panandikar, Managing Director of Indoco Remedies, commented, "The ANDA approval for brivaracetam is a significant milestone for us as we continue to strengthen our presence in the regulated markets. We are committed to offering innovative and affordable healthcare to patients worldwide."Indoco Remedies is a fully integrated, research-based, pharmaceutical firm that is globally based. The company employs over 6000 people, including 400 hardened scientists, with a turnover of USD 180 million.Indico has 10 manufacturing plants, six Finished Dosage Forms(FDFs) plants, and four Active Pharmaceutical Ingredients(APIs) plants, which are approved by regulatory agencies such as the US FDA and UK-MHRA. POEris Lifesciences has announced a partnership with Natco Pharma for the commercialization of semaglutide in India, strengthening its footprint in the fast-growing diabetes and obesity treatment market.The agreement comes as the patent on semaglutide, the key ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic, is set to expire in certain markets, including India, this March.Semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes and weight loss. With the patent expiry nearing, several Indian drugmakers such as Dr Reddy's Laboratories, Lupin, Cipla, and Sun Pharma are preparing to introduce generic versions. The entry of semaglutide is expected to intensify competition in the domestic market.The 2,894-crore Eris Lifesciences has steadily built a strong presence in diabetology. The addition of semaglutide is seen as a strategic move to deepen its diabetes portfolio and tap into rising demand for advanced therapies. Under the collaboration, Natco Pharma will leverage its expertise in manufacturing and regulatory approvals for complex formulations, while Eris will drive commercialization through its established sales network in chronic therapies.Natco Pharma has already secured regulatory approval in India, clearing the path for a launch in March 2026. Amit Bakshi, Eris Lifesciences Chairman and Managing Director, said, "This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies...Eris is well positioned to drive rapid adoption and enhance patient access in India." PO
< Page 8 | Page 10 >